SS-31 vs Dihexa: Mechanism, Half-Life & Research Use
While both SS-31 and Dihexa are widely evaluated in preclinical models of cellular repair and cognitive decay, their underlying mechanisms operate through entirely distinct biological pathways. SS-31 primarily targets inner mitochondrial membrane integrity via cardiolipin binding, whereas Dihexa functions as an angiotensin IV-derived agonist of the HGF/c-Met pathway to promote dendritic arborization.
Quick answer
While both SS-31 and Dihexa are widely evaluated in preclinical models of cellular repair and cognitive decay, their underlying mechanisms operate through entirely distinct biological pathways. SS-31 primarily targets inner mitochondrial membrane integrity via cardiolipin binding, whereas Dihexa functions as an angiotensin IV-derived agonist of the HGF/c-Met pathway to promote dendritic arborization.
Key takeaways
- In laboratory research settings, [SS-31](/research-peptides/ss-31) and [Dihexa](/research-peptides/dihexa) serve fundamentally different analytical purposes.
- | Research Parameter | [SS-31](/research-peptides/ss-31) (Elamipretide) | [Dihexa](/research-peptides/dihexa) (PNB-0408) | | :--- | :--- | :--- | | **Primary Receptor / Target** | Inner mitochondrial membrane cardiolipin | Hepatocyte Growth Factor (HGF) / c-Met receptor | | **Mechanistic Class** | Mitochondria-targeted antioxidant & bioenergetic stabilizer | Neurotrophic growth factor mimetic / Synaptogenic agonist | | **Reported Half-Life (Preclinical)** | ~2 to 4 hours (plasma); extended tissue retention in mitochondria | ~2 to 12 hours (variable by species/model) | | **Solubility Profile** | Highly water-soluble (aqueous buffers, saline) | Moderately hydrophobic (requires DMSO or organic co-solvents) | | **Typical Preclinical Models** | Ischemia-reperfusion, cardiotoxicity, mitochondrial decay, aging | Neurodegeneration, synaptic plasticity, traumatic brain injury (TBI) | | **Vial Sizes Available** | 10mg, 50mg (lyophilized powder) | 10mg, 50mg (lyophilized powder) |
- [SS-31](/research-peptides/ss-31) (D-Arg-Dmt-Lys-Phe-NH2) is an aromatic-cationic tetrapeptide designed to freely penetrate cell membranes and concentrate over 1,000-fold within the inner mitochondrial membrane (IMM).
- [Dihexa](/research-peptides/dihexa) (N-hexanoic-Tyr-Ile-Ala-NH2) was synthesized as a stable, lipophilic peptide fragment capable of mimicking the neurotrophic activity of Angiotensin IV.
Comparative Summary: Primary Differences Between SS-31 and Dihexa
In laboratory research settings, SS-31 and Dihexa serve fundamentally different analytical purposes. SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that selectively interacts with cardiolipin to stabilize inner membrane cristae structure, suppress reactive oxygen species (ROS) emission, and restore ATP synthase kinetics. In contrast, Dihexa (PNB-0408) is a hexapeptide analog derived from angiotensin IV designed to bind hepatocyte growth factor (HGF) with high affinity, activating the c-Met receptor tyrosine kinase pathway to drive synaptogenesis and spinogenesis in neuronal tissue assays.
Researchers evaluating cellular bioenergetics, ischemia-reperfusion injury, or metabolic stress typically select SS-31 due to its localized mitochondrial activity. Investigators focused on neurostructural plastic changes, dendritic spine density, or memory deficit reversal models frequently select Dihexa. Reviewing our comprehensive catalog of all peptides allows researchers to identify the appropriate biochemical probes for their specific experimental parameters.
Technical Comparison Matrix: SS-31 vs. Dihexa
| Research Parameter | SS-31 (Elamipretide) | Dihexa (PNB-0408) | | :--- | :--- | :--- | | **Primary Receptor / Target** | Inner mitochondrial membrane cardiolipin | Hepatocyte Growth Factor (HGF) / c-Met receptor | | **Mechanistic Class** | Mitochondria-targeted antioxidant & bioenergetic stabilizer | Neurotrophic growth factor mimetic / Synaptogenic agonist | | **Reported Half-Life (Preclinical)** | ~2 to 4 hours (plasma); extended tissue retention in mitochondria | ~2 to 12 hours (variable by species/model) | | **Solubility Profile** | Highly water-soluble (aqueous buffers, saline) | Moderately hydrophobic (requires DMSO or organic co-solvents) | | **Typical Preclinical Models** | Ischemia-reperfusion, cardiotoxicity, mitochondrial decay, aging | Neurodegeneration, synaptic plasticity, traumatic brain injury (TBI) | | **Vial Sizes Available** | 10mg, 50mg (lyophilized powder) | 10mg, 50mg (lyophilized powder) |
This comparative matrix summarizes the primary physiological and biochemical distinctions between the two compounds. Detailed analytical testing data and lot verification documents are accessible through our COA portal.
SS-31 Mechanism of Action: Cardiolipin Binding and Bioenergetics
SS-31 (D-Arg-Dmt-Lys-Phe-NH2) is an aromatic-cationic tetrapeptide designed to freely penetrate cell membranes and concentrate over 1,000-fold within the inner mitochondrial membrane (IMM). Preclinical studies indicate that SS-31 binds electrostatically and hydrophobically to cardiolipin, a unique phospholipid essential for maintaining mitochondrial cristae curvature and organizing respiratory chain supercomplexes (respirasomes).
By stabilizing cardiolipin, SS-31 prevents electron leakage along the electron transport chain (ETC), thereby diminishing the formation of toxic superoxide anions without disrupting normal cell signaling ROS. In vitro assays demonstrate that cardiolipin protection by SS-31 preserves cytochrome c electron transfer efficiency, inhibits permeability transition pore (mPTP) opening, and maintains ATP production under hypoxia or severe oxidative stress conditions.
Dihexa Mechanism of Action: HGF/c-Met Activation and Synaptogenesis
Dihexa (N-hexanoic-Tyr-Ile-Ala-NH2) was synthesized as a stable, lipophilic peptide fragment capable of mimicking the neurotrophic activity of Angiotensin IV. In vitro binding assays reveal that Dihexa binds to hepatocyte growth factor (HGF) with picomolar affinity ($K_d \approx 1.0 \times 10^{-12}$ M), facilitating HGF dimerization and subsequent phosphorylation of the c-Met receptor tyrosine kinase.
Activation of the HGF/c-Met signaling axis triggers downstream intracellular cascades, including the MAPK/ERK and PI3K/Akt pathways. Preclinical rodent models indicate that this signal transduction enhances dendritic spine building, increases post-synaptic density 95 (PSD-95) expression, and promotes the formation of functional synaptic linkages at significantly lower molar concentrations than native neurotrophins such as brain-derived neurotrophic factor (BDNF).
Pharmacokinetics, Half-Life, and Tissue Distribution
In animal pharmacokinetics, SS-31 exhibits rapid systemic distribution followed by specific accumulation in mitochondria-rich tissues, such as cardiac, renal, and skeletal muscle cells, as well as cerebral tissue. While plasma elimination half-life in rodent models is relatively short (approximately 2 hours), the intra-mitochondrial retention time of SS-31 is significantly longer due to its high affinity for cardiolipin complexes.
Dihexa possesses enhanced metabolic stability compared to native linear peptides due to its modified N-terminal hexanoyl moiety. Preclinical pharmacokinetic evaluations indicate an extended half-life in systemic circulation compared to standard neuropeptides. Because of its lipophilic character, Dihexa exhibits potential blood-brain barrier permeability in animal studies, allowing researchers to evaluate central nervous system endpoints via peripheral or systemic administration routes in rodent models.
Comparing SS-31 and Dihexa with Related Research Peptides
To properly position SS-31 and Dihexa within a broader experimental context, researchers often compare them against other mitochondrial and neurotrophic modulators. For example, MOTS-c is a mitochondria-derived peptide that regulates nuclear gene expression and metabolic homeostasis, contrasting with SS-31’s direct biophysical interaction with cardiolipin. While SS-31 preserves organelle integrity, MOTS-c acts primarily as a metabolic signaling molecule involved in glucose regulation and exercise-mimetic pathways.
Similarly, when evaluating neuroplasticity and cognitive function, researchers often compare Dihexa with Semax, Selank, and N-Acetyl Semax Amidate. While Semax and its analogs primarily modulate BDNF and trkB receptor expression along with neurotransmitter turnover, Dihexa operates directly through HGF/c-Met receptor dimerization. Understanding these mechanistic variances allows scientists to choose the precise molecular probe suited to their specific study parameters.
Solvent Compatibility and Reconstitution Protocols
Reconstitution protocols differ substantially between SS-31 and Dihexa due to their contrasting chemical structures and hydrophobicities. SS-31 contains hydrophilic residues and readily dissolves in standard aqueous media, such as sterile water, phosphate-buffered saline (PBS), or normal saline (0.9% NaCl), reaching high solubility thresholds without aggregation.
Dihexa, conversely, features an N-terminal fatty acid chain that imparts hydrophobic properties. Researchers often require non-ionic surfactants, dilute acetic acid, or dimethyl sulfoxide (DMSO) as a primary stock solvent prior to dilution in aqueous assay buffers to prevent precipitation. For precise volumetric calculations, concentration adjustments, and molarity calculations across varying experimental volumes, researchers can utilize our free online reconstitution calculator.
Selecting the Optimal Compound for Experimental Design
Choosing between SS-31 and Dihexa depends entirely on the primary hypothesis and cellular target of the laboratory trial. If the experimental objective centers on mitochondrial ROS management, organelle structure preservation, ischemia-reperfusion models, or metabolic bioenergetics, SS-31 provides a validated, cardiolipin-targeted intervention point.
Conversely, if the experimental paradigm requires measuring synaptogenesis, dendritic arborization, synaptic repair following mechanical injury, or HGF/c-Met pathway activity, Dihexa serves as the superior experimental tool. For extensive comparative literature, mechanistic whitepapers, and scientific resources, explore our research hub or contact our team regarding wholesale institutional lab supply contracts.
PX1 Research Analytical Quality Verification
All research peptides supplied by PX1 Research are manufactured in state-of-the-art facilities located in the USA that strictly adhere to GMP-compliant operational standards. Each product lot undergoes rigorous quality control testing in an independent, ISO 17025-accredited analytical laboratory to confirm molecular identity and chemical purity.
We utilize High-Performance Liquid Chromatography (HPLC) coupled with Mass Spectrometry (MS) to verify that compound purity exceeds 99%. Additionally, our products undergo quantitative chromogenic LAL assays to ensure endotoxin limits remain far below strict laboratory research thresholds. Every shipment includes lot-specific documentation verifying these purity metrics.
Frequently Asked Questions
What is the primary mechanistic difference between SS-31 and Dihexa?
SS-31 works by directly binding to cardiolipin inside the inner mitochondrial membrane to optimize bioenergetics and minimize ROS emission. Dihexa acts as an agonist of the HGF/c-Met signaling axis to stimulate synaptogenesis and dendritic spine growth.
Are SS-31 and Dihexa soluble in the same reconstitution solvents?
No. SS-31 is highly water-soluble and easily dissolves in aqueous solutions like sterile water or PBS. Dihexa is more hydrophobic and generally requires DMSO or organic co-solvents for stock solution preparation before dilution.
What preclinical models are most suitable for SS-31 research?
SS-31 is commonly evaluated in preclinical models of ischemia-reperfusion injury, heart failure, acute kidney injury, age-related mitochondrial dysfunction, and oxidative stress conditions.
What preclinical models are most suitable for Dihexa research?
Dihexa is frequently utilized in neurodegenerative models, traumatic brain injury assays, synaptogenesis research, and cognitive deficit studies in rodents.
How should lyophilized SS-31 and Dihexa vials be stored in the lab?
Lyophilized vials should be stored at -20°C for long-term stability. Once reconstituted, stock aliquots should be kept at -80°C to prevent peptide degradation and avoid repeated freeze-thaw cycles.
Where are PX1 Research peptides manufactured and tested?
All PX1 Research compounds are manufactured in USA-based facilities adhering to GMP standards and verified by third-party ISO 17025-accredited analytical testing laboratories.
What purity levels and endotoxin limits does PX1 guarantee?
PX1 Research guarantees peptide purity of ≥99% as confirmed by HPLC/MS testing, with endotoxin levels strictly controlled and verified via chromogenic LAL assays.
Can SS-31 or Dihexa be used in clinical or veterinary applications?
No. All products supplied by PX1 Research are strictly for laboratory in vitro and preclinical research use only. They are not for human or animal therapeutic, diagnostic, or clinical use.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.